61,790 Shares in Zimmer Biomet Holdings, Inc. $ZBH Bought by Corient Private Wealth LP

Corient Private Wealth LP bought a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the second quarter, HoldingsChannel.com reports. The firm bought 61,790 shares of the medical equipment provider’s stock, valued at approximately $5,320,000.

Several other large investors also recently bought and sold shares of the company. Dodge & Cox increased its position in shares of Zimmer Biomet by 1.3% in the fourth quarter. Dodge & Cox now owns 23,506,849 shares of the medical equipment provider’s stock valued at $2,113,736,000 after buying an additional 290,676 shares in the last quarter. BlackRock Inc. acquired a new position in Zimmer Biomet during the second quarter worth about $1,344,282,000. State Street Corp raised its position in Zimmer Biomet by 2.3% during the fourth quarter. State Street Corp now owns 8,826,974 shares of the medical equipment provider’s stock worth $795,814,000 after acquiring an additional 195,214 shares during the last quarter. Franklin Resources Inc. lifted its holdings in shares of Zimmer Biomet by 43.2% in the fourth quarter. Franklin Resources Inc. now owns 6,685,987 shares of the medical equipment provider’s stock valued at $601,204,000 after purchasing an additional 2,017,857 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Zimmer Biomet by 0.7% in the fourth quarter. Geode Capital Management LLC now owns 5,233,834 shares of the medical equipment provider’s stock valued at $468,821,000 after purchasing an additional 36,611 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Trading Down 0.7%

Shares of Zimmer Biomet stock opened at $100.19 on Tuesday. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $79.12 and a fifty-two week high of $106.88. The firm has a market cap of $19.11 billion, a PE ratio of 24.38, a P/E/G ratio of 2.74 and a beta of 0.45. The business’s fifty day moving average is $94.14 and its two-hundred day moving average is $91.52. The company has a quick ratio of 0.94, a current ratio of 1.69 and a debt-to-equity ratio of 0.50.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.01 by $0.06. The business had revenue of $2.18 billion for the quarter, compared to analysts’ expectations of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The business’s revenue was up 4.8% on a year-over-year basis. During the same quarter last year, the firm earned $2.07 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.54 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date of this dividend is Wednesday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 23.36%.

Wall Street Analysts Forecast Growth

ZBH has been the subject of a number of recent research reports. Royal Bank Of Canada raised their price objective on shares of Zimmer Biomet from $101.00 to $110.00 and gave the stock an “outperform” rating in a research note on Thursday, August 6th. BMO Capital Markets reaffirmed a “market perform” rating and issued a $96.00 target price on shares of Zimmer Biomet in a research note on Thursday, August 6th. Robert W. Baird set a $104.00 target price on Zimmer Biomet in a report on Thursday, August 6th. Weiss Ratings raised Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, August 4th. Finally, Sanford C. Bernstein boosted their price target on Zimmer Biomet from $91.00 to $93.00 and gave the stock a “market perform” rating in a report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $104.42.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.